New gene therapy research offers hope for people with chronic kidney disease

OHSU team identifies how various delivery routes reach kidney cells differently, paving way for more effective treatments

By Angela Yeager December 30, 2024 Portland, Oregon

Lea esta página en español

Downloads

Nakai research

Injecting adeno-associated virus, or AAV, vectors into the kidney of a non-human primate using a catheter led to strong gene activity (shown in red) in the kidney's proximal tubules, even if there was already the primate already had an immune response to AAV. (Courtesy)

Hiroyuki Nakai team

Group, from Left: Hideyuki Hakui, M.D., Ph.D., a postdoc; Pratheppa Rajagopal, Ph.D., a postdoc; Swapna Kollu, Ph.D., a senior research associate; Hiroyuki Nakai, M.D., Ph.D., professor of Molecular and Medical Genetics and of Molecular Microbiology and Immunology in the OHSU School of Medicine; Hiroyuki Nakashima, Ph.D.; Anusha Sairavi, M.S., a research associate and lab manager; Lena Li, M.D., a research associate; Siddhi Narvekar, M.S., a research assistant 2; and Ranjan Das, Ph.D., a staff scientist. (OHSU/Christine Torres Hicks)

Hiroyuki Nakai, M.D., Ph.D. (OHSU)

Taisuke Furusho, M.D., Ph.D. (Courtesy)

Hiroyuki Nakai Lab

Hiroyuki Nakai, M.D., Ph.D., works with his team in his Department of Molecular and Medical Genetics lab in the OHSU School of Medicine. Nakai and his team have identified ways to improve gene delivery to the kidney, paving the way for more effective treatments. (OHSU/Christine Torres Hicks)